ARTV - Artiva Biotherapeutics, Inc.

1.92
-1.390   -72.396%

Share volume: 1,316,594
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$3.31
-1.39
-0.42%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 0%
Dept financing 25%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-21.31%
1 Month
-63.84%
3 Months
-79.47%
6 Months
-87.04%
1 Year
-84.00%
2 Year
-84.00%
Key data
Stock price
$1.92
P/E Ratio 
N/A
DAY RANGE
$1.85 - $2.96
EPS 
-$23.03
52 WEEK RANGE
$1.85 - $17.31
52 WEEK CHANGE
-$84.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
24.287 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,519,852
AVERAGE 30 VOLUME 
$587,759
Company detail
CEO: Fred Aslan
Region: US
Website: www.artivabio.com
Employees: 0
IPO year: 2024
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California.

Recent news
loading